CN116077611A - Traditional Chinese medicine compound with yang warming and heart benefiting effects - Google Patents
Traditional Chinese medicine compound with yang warming and heart benefiting effects Download PDFInfo
- Publication number
- CN116077611A CN116077611A CN202211545715.6A CN202211545715A CN116077611A CN 116077611 A CN116077611 A CN 116077611A CN 202211545715 A CN202211545715 A CN 202211545715A CN 116077611 A CN116077611 A CN 116077611A
- Authority
- CN
- China
- Prior art keywords
- parts
- decoction
- compound
- medicine
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 238000010792 warming Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims description 42
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 13
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- 241001522129 Pinellia Species 0.000 claims abstract description 7
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 7
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 7
- 235000011477 liquorice Nutrition 0.000 claims abstract description 7
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 6
- 244000197580 Poria cocos Species 0.000 claims abstract description 6
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 6
- 241000756943 Codonopsis Species 0.000 claims abstract description 5
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 5
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 4
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 4
- 235000008397 ginger Nutrition 0.000 claims abstract description 4
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 3
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 3
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 25
- 206010008479 Chest Pain Diseases 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 10
- 206010033557 Palpitations Diseases 0.000 claims description 9
- 206010063659 Aversion Diseases 0.000 claims description 8
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 7
- 241000217407 Margaritifera Species 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 241000237502 Ostreidae Species 0.000 claims description 5
- 235000020636 oyster Nutrition 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 210000001015 abdomen Anatomy 0.000 claims description 4
- 210000003414 extremity Anatomy 0.000 claims description 4
- 240000006079 Schisandra chinensis Species 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 210000003141 lower extremity Anatomy 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 206010040007 Sense of oppression Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 abstract description 19
- 238000003745 diagnosis Methods 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 11
- 201000000057 Coronary Stenosis Diseases 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000007012 clinical effect Effects 0.000 abstract description 6
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 14
- 208000026435 phlegm Diseases 0.000 description 14
- 230000036772 blood pressure Effects 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 10
- 208000031481 Pathologic Constriction Diseases 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 230000036262 stenosis Effects 0.000 description 10
- 208000037804 stenosis Diseases 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 208000000059 Dyspnea Diseases 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 8
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 8
- 239000000006 Nitroglycerin Substances 0.000 description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 229960003711 glyceryl trinitrate Drugs 0.000 description 8
- 208000013220 shortness of breath Diseases 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 244000248557 Ophiopogon japonicus Species 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 244000183685 Citrus aurantium Species 0.000 description 4
- 235000007716 Citrus aurantium Nutrition 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- 208000031975 Yang Deficiency Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000023482 precordial pain Diseases 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 229940093265 berberine Drugs 0.000 description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000007126 Codonopsis pilosula Species 0.000 description 2
- 206010011089 Coronary artery stenosis Diseases 0.000 description 2
- 241000234276 Curculigo Species 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 241001673966 Magnolia officinalis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 244000179560 Prunella vulgaris Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000244155 Taenia Species 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 244000237330 gutta percha tree Species 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000008113 selfheal Nutrition 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001108921 Asclepias asperula Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102100021217 Dual oxidase 2 Human genes 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000096284 Gynochthodes officinalis Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 description 1
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese herbal compound with the effects of warming yang and tonifying heart is characterized in that: comprises the following components: 5-30 parts of radix codonopsis pilosulae, 5-30 parts of dwarf lilyturf tuber, 5-15 parts of coptis chinensis, 5-30 parts of snakegourd fruit, 5-30 parts of allium macrostemon, 5-9 parts of pinellia tuber, 5-30 parts of cassia twig, 5-30 parts of red paeony root, 5-30 parts of poria cocos, 5-20 parts of szechuan lovage rhizome, 5-15 parts of liquorice, 5-15 parts of ginger and 5-15 parts of Chinese date. The invention can obviously improve the symptoms of coronary heart disease and angina pectoris, dilate coronary stenosis, greatly improve the clinical curative effect and long-term benefit of coronary heart disease diagnosis and treatment, has obvious clinical effect, and is safe and reliable.
Description
Technical Field
The invention relates to the technical field of prescriptions for coronary heart disease, in particular to a traditional Chinese medicine compound with yang warming and heart benefiting effects.
Background
Several limitations of current coronary heart disease treatment methods: the comprehensive benefit is poor: coronary lesions are a lengthy pathological evolution process, and common antiplatelet drugs cannot participate in the plaque formation process, and the simple lipid-lowering treatment is also a cup-made salary. The current interventional therapy widely used for coronary heart disease treatment can not significantly reduce the occurrence and death rate of myocardial infarction. We still need to explore better coronary heart disease treatment methods that benefit from the combination. The safety is not enough: most of the side effects of western medicines are beneficial to the western medicines. Aspirin is the most commonly used secondary preventive drug for coronary heart disease, but also greatly increases the risk of bleeding events of elderly patients, so that many elderly people are in an embarrassing situation of no drug availability. In addition, statins are the primary lipid-lowering drugs, but their widespread myolytic pain and impairment of liver function makes many patients prohibitive.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a traditional Chinese medicine compound with the effects of warming yang and tonifying heart, which essentially solves the problems.
Technical proposal
In order to achieve the above purpose, the invention is realized by the following technical scheme:
a Chinese medicinal compound with yang warming and heart benefiting effects comprises the following components: 5-30 parts of radix codonopsis pilosulae, 5-30 parts of dwarf lilyturf tuber, 5-15 parts of coptis chinensis, 5-30 parts of snakegourd fruit, 5-30 parts of allium macrostemon, 5-9 parts of pinellia tuber, 5-30 parts of cassia twig, 5-30 parts of red paeony root, 5-30 parts of poria cocos, 5-20 parts of szechuan lovage rhizome, 5-15 parts of liquorice, 5-15 parts of ginger and 5-15 parts of Chinese date.
Preferably, the astragalus root is added by 10-60 parts for regulating chest distress and shortness of breath.
Preferably, 3-10 parts of schisandra chinensis, 10-50 parts of raw dragon bone, 10-50 parts of raw oyster and 10-50 parts of mother-of-pearl are added for regulating insomnia and palpitation.
Preferably, 10 parts of cassia twig are added, and all parts of coptis chinensis are removed, so that the Chinese medicinal composition is used for regulating aversion to cold and cold limbs.
Preferably, the bitter orange is added in an amount of 5-20 parts for regulating chest and abdomen fullness and oppression.
Preferably, 5 parts of coptis chinensis is added, and the total parts of dwarf lilyturf tuber are removed, so that the yellow and thick tongue coating is regulated.
Preferably, 5-20 parts of curculigo rhizome, 5-20 parts of eucommia ulmoides and 5-20 parts of morinda officinalis are added for regulating waist soreness, aversion to cold and weakness of lower limbs.
A compound decoction method is characterized in that:
step one, soaking a compound medicine in clear water before decocting;
step two, pouring the compound medicine into a marmite for first decoction after soaking, wherein the water adding amount exceeds the medicine surface by 10 cm;
step three, decocting the first decoction for 40 minutes after boiling, pouring out the first decoction, and reserving the first decocted compound medicine;
step four, performing second decoction on the compound medicine after the first decoction, wherein the second decoction water quantity is smaller than the first decoction water quantity, boiling, then decocting for 30 minutes, and pouring out the second decoction;
and fifthly, mixing the first decoction amount with the second decoction amount.
Preferably, the compound medicine in the first step is soaked for 30 minutes if the compound medicine is a leaf-type or grass-type Chinese medicine, and soaked for one hour if the compound medicine is a mineral-type Chinese medicine; the mineral Chinese medicinal materials include Os Draconis, concha Ostreae and Concha Margaritifera.
Preferably, the materials are boiled with strong fire when not boiled, and are boiled with small fire, and the materials are continuously stirred in the boiling process.
Advantageous effects
The invention greatly improves the clinical curative effect and long-term benefit of coronary heart disease diagnosis and treatment, has obvious clinical effect and is safe and reliable. The compound can greatly improve the symptoms of coronary heart disease and angina pectoris, and simultaneously improve pathological coronary stenosis and atheromatous plaque.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The compound common components of the invention are as follows: radix codonopsis pilosulae (5-30 g), radix ophiopogonis (5-30 g), coptis chinensis (5-15 g), snakegourd fruit (5-30 g), allium macrostemon (5-30 g), pinellia ternate (5-9 g), cassia twig (5-30 g), red paeony root (5-30 g), poria cocos (5-30 g), ligusticum wallichii (5-20 g), liquorice (5-15 g), ginger (5-15 g) and jujube (5-15 g). The components can be flexibly adjusted in practical application, and the specific adjustment method is as follows: for chest distress and short breath, radix astragali 10-60g can be added; for patients with insomnia and palpitation, 3-10g of fructus Schisandrae chinensis, 10-50g of Os Draconis, 10-50g of Concha Ostreae and 10-50g of Concha Margaritifera can be added; for those with severe cold limbs and pale tongue, 10g of ramulus Cinnamomi can be added and rhizoma Coptidis is removed; for chest and abdomen fullness and distention, fructus Aurantii Immaturus 5-20g is added; for those with yellow and thick tongue fur, 5g of coptis chinensis and ophiopogon root can be added; for patients with soreness of waist, aversion to cold and weakness of lower limbs, 5-20g of rhizoma Curculiginis, 5-20g of cortex Eucommiae and 5-20g of radix Morindae officinalis can be added.
The decoction method comprises the following steps:
preparation: the environment of the marmite, the clean water and the cooking range should be spacious and ventilated.
The decocting flow is as follows: before decocting, the Chinese medicinal materials are soaked in clear water, and generally leaf and grass Chinese medicinal materials can be soaked for about 30 min, and mineral substances (Os Draconis, concha Ostreae, concha Margaritifera) can be soaked for about one hr. After the soaking, the medicine is poured into a marmite for first decoction, and the water adding amount is preferably about 10 cm above the surface of the medicine. The second decoction should be reduced and the tonic Chinese medicinal should be added with water.
The decoction time is as follows: boiling the first decoction, and decocting for 40 minutes; the second decoction is boiled and decocted for 30 minutes. Wherein Os Draconis, concha Ostreae, and Concha Margaritifera are decocted for 30 min.
Mastering the fire: when not boiling, the mixture is boiled with intense fire (big fire) and then boiled with slow fire (small fire), and the mixture needs to be stirred frequently during the boiling process.
Number and amount of decoction: each pair of traditional Chinese medicine needs to be decocted twice, the dosage of each decoction is about 150 milliliters, the two decocted dosages are mixed together to be 300 milliliters, and the mixture is divided into 2 or 3 parts for each time in the morning (in the middle) and evening.
The compound prescription has the main advantages that:
(1) Obvious clinical effects: the compound is prepared by several decades of clinical researches and practices, and has remarkable clinical effect of treating coronary heart disease. Clinical studies show that the rate of improvement of the symptoms of angina pectoris reaches 90.0%, the average stenosis degree of coronary stenosis is reduced (16.45+/-31.25)% (P < 0.01) after treatment, and the 43 parts of the stenosis at 76 parts of more than or equal to 50% disappear or reverse.
(2) Basic research is full: animal experiments show that the method can reduce the Atherosclerosis (AS) model rabbit aortic atherosclerosis plaque area by 54-58%, obviously reduce AS model rat atherosclerosis index and improve AS pathological changes of coronary arteries and aorta. The action mechanism of the 'yang warming and heart tonifying method' for resisting AS is various, and early researches show that the 'yang warming and heart tonifying method' can obviously reduce the CHO and LDL-C levels of AS rabbits, raise the HDL-C level and lighten lipid infiltration; inhibiting NF- κB activation of AS rat, reducing CRP and IL-6 content, and inhibiting inflammatory reaction; regulating and controlling various coagulation factors, inhibiting platelet aggregation and adhesion, and resisting thrombosis; meanwhile, the AS rat PI3K/AKT signal path is mediated, eNOS expression is promoted, and simultaneously, ET-1, ox-LDL and Ang II are synthesized and released, so that endothelial cell injury is relieved. All the above studies suggest a remarkable therapeutic effect of the recipe on atherosclerosis.
Safety and reliability: the Chinese herbal medicine compound composition is a Chinese herbal medicine commonly used in clinic, and has thousands of years of application history. Adverse reactions were not found in the relevant clinical and basic studies. In conclusion, the method has reliable safety.
The chemical components of each traditional Chinese medicine are searched by using a TCMSP database (https:// tcmspw.com/tcmsp.php), and a 0B value (bioavailability) is more than or equal to 30% and a DL value (component similarity) is more than or equal to 0.18 as screening standards. The co-screening method contains 97 main medicinal compounds, and the details are shown in table 1.
TABLE 1 information table of the effective ingredients of the formulations
Naringenin belongs to flavonoid compounds, is one of main medicinal components of allium macrostemon, is a natural superoxide and peroxy radical scavenger, and has remarkable antioxidation and anti-inflammatory effects. Naringin inhibits proliferation and migration of VSMC (vascular smooth muscle cells) in vitro and proliferation of neointima and lipid streaks in vivo through MAPK/NF- κB signaling pathway. Naringin also reduces the severity of endothelial dysfunction by modulating NO bioavailability and oxidative stress, and protects infarcted and ischemia damaged myocardium by improving mitochondrial function.
Stigmasterol and beta-sitosterol exist in medicines such as radix codonopsis pilosulae, radix paeoniae rubrathe and rhizoma pinelliae, can competitively inhibit the absorption of cholesterol (TC), induce the expression of cholesterol transporter-ABCA/ABCG series proteins, inhibit the uptake of modified lipoprotein by macrophages in the inflammatory process, and thus inhibit the processes of intra-plaque inflammation and lipid deposition. Can regulate multiple pathways to play a role in protecting I/R myocardium, and reduce ischemia/reperfusion injury and myocardial apoptosis area after infarction. And a plurality of researches prove that the stigmasterol and the beta-sitosterol have the functions of delaying arteriosclerosis and reversing arterial plaque
Quercetin (quercetin) is one of main components of ginseng, allium macrostemon, coptis chinensis and liquorice, has active hydroxyl groups in the structure, can reduce the formation of Reactive Oxygen Species (ROS) by inhibiting nicotinamide adenine dinucleotide phosphate oxidase and xanthine oxidase, inhibit the activities of Cyclooxygenase (COX) and Lipoxygenase (LOX), regulate the signal activity in inflammatory response cells, and has various characteristics such as antioxidation, endothelial protection, vasodilation and the like. Studies have shown that after 2 months of treatment with quercetin, the IL-1b, TNF-a and IL-10 values of patients with coronary heart disease are reduced to varying degrees, whereas intravenous injection of quercetin can reduce the size of Acute Myocardial Infarction (AMI) necrosis. The coptis contains a plurality of important medicinal components such as berberine (berberine), berberine (coptisine), palmatine hydrochloride (palmatine) and the like, can activate PI3K-Akt channels, increase the content of HIF1Q, promote the HIF-1 channel-mediated Sphk2 transcription and AMPK phosphorylation, and thus protect the non-ischemic region of the heart.
The method is applied to clinic for over 20 years, is widely used for diagnosing and treating the coronary heart disease for nearly 1 ten thousand times, has obvious clinical effect, is safe and reliable, does not find obvious adverse reaction, and is favored by patients with the coronary heart disease. The traditional treatment method can not essentially treat the cause of coronary heart disease for a long time, so the clinical effect is not satisfactory. The composition can improve coronary heart disease and angina pectoris, and also improve pathological coronary stenosis and atheromatous plaque. The mean stenosis degree of coronary artery stenosis is reduced (16.45+/-31.25)% (P < 0.01) after treatment, and the 43 is disappeared or reversed in 76-site stenosis more than or equal to 50%.
Case 1: the patient, male, 58 years old, needs to take nitroglycerin for 1 year's relief due to chest distress, shortness of breath, acid deposition on the back, at the first diagnosis of 4 months and 9 days in 2012. Chest distress, shortness of breath, acid sinking of the back, aversion to cold, fever at night, bitter taste at the even mouth, pale tongue with ecchymosis, yellow and little body fluid coating, wiry and slippery pulse. Coronary angiography shows: 100% of the 1 st diagonal branch is blocked, 90% of the right coronary artery middle section is stenosed, and 80% of the left anterior descending branch middle section is stenosed. Electrocardiographic representation: STII, III, avF, v2-v6 move down. Blood pressure 170/100mmHg. The past history of hypertension was 10 years. Western diagnosis: coronary heart disease. Diagnosis of traditional Chinese medicine: chest stuffiness is caused by heart yang failing to control blood stasis and phlegm stagnation, and liver yang hyperactivity is treated by warming yang and tonifying heart, activating blood and resolving phlegm, and suppressing liver yang. The prescription comprises the following components: 30g of selfheal, 20g of cassia seed, 20g of dangshen, 15g of dwarf lilyturf tuber, 10g of coptis chinensis, 15g of purified pinellia tuber, 15g of snakegourd fruit, 15g of longstamen onion bulb, 15g of red paeony root, 15g of szechuan lovage rhizome, 15g of Indian buead, 30g of raw dragon bone (decocted first), 30g of raw oyster (decocted first) and 10g of liquoric root. 20 doses, 1 dose daily, are decocted in water and taken 3 times.
Two diagnoses at 2012, 4 and 28 days: chest distress and shortness of breath are alleviated, body heat is alleviated at night, but there is discomfort in the precordial region and acid deposition in the back at the afternoon. Blood pressure 130/100mmHg. A pale-red and slightly purple tongue with a coating Huang Hua and a slippery pulse. Above, os Draconis and Concha Ostreae are removed, and fructus Aurantii Immaturus 15g, caulis Bambusae in Taenia 15g, ramulus Cinnamomi 10g, and ramulus Uncariae cum Uncis 30g are added. 30 doses are decocted and taken as before.
Three diagnoses in 2012, 5 and 27 days: precordial discomfort, stopping taking nitroglycerin, shortness of breath, heavy back, nausea in the morning, and discomfort at the corners of the mouth. Blood pressure 140/95mmHg. Pale-red and slightly purple tongue with thin and yellow coating, smooth pulse. Fructus Aurantii Immaturus and ramulus Cinnamomi are removed from the upper part, and rhizoma Polygonati 15g, rhizoma Curculiginis 10g and Os Draconis 30g (decocted first) are added. 30 doses are decocted and taken as before.
Four diagnoses at 2012, 7, 1 and four days: all symptoms disappear, and no obvious discomfort is caused. Blood pressure 130/85mmHg. The medicine is continuously taken for 270 doses by the conservation therapy. Coronary CT for 27 sun-checks at 2013, 4, month: the 1 st diagonal stenosis (25% -49%), the middle of the right coronary artery and the middle of the left anterior descending branch were moderately severe (50% -89%) and the electrocardiogram was approximately normal. The patient is treated by the method, has no obvious discomfort after 5 years of diagnosis, has normal electrocardiograph and biochemical indexes, and has no occurrence of cardiovascular accidents.
In terms of: the patient can show symptoms of liver yang hyperactivity such as hypertension, bitter taste, and fever besides typical heart yang deficiency, blood stasis and phlegm coagulation, and Prunellae Spica, semen Cassiae, ramulus Uncariae cum Uncis, os Draconis, and Concha Ostreae are added to calm liver and suppress yang based on warming yang and benefiting heart, promoting blood circulation and eliminating phlegm. 2. In three cases, blood pressure is lowered, body heat is not obvious, but symptoms of yang deficiency and phlegm heat are obvious, so ramulus Cinnamomi and rhizoma Curculiginis are added to excite heart yang, fructus Aurantii Immaturus and caulis Bambusae in Taenia clear heat and resolve phlegm. The daemon therapy is used for more than 1 year, and the clinical symptoms, coronary stenosis degree and electrocardiogram are obviously improved.
Case 2 implementation: patients, men, 64 years old, need to take nitroglycerin to relieve due to chest distress and precordial pain, and the first diagnosis is made on 2 months and 23 days after activity, more than 2 months after activity. The following symptoms: chest distress, precordial pain, palpitation, back pain, abdominal distention and obvious afternoon. Coronary CT shows: the first diagonal branch is occluded (100%), the left anterior descending branch is severely stenosed (75% -89%), and the right coronary artery is moderately stenosed (50% -75%). Dynamic electrocardiogram: ventricular premature contraction 5253 times/24 h with bivariate rhythm. The past history of hypertension is 3 years, and the history of diabetes is 10 years. Blood pressure 148/88mmHg. A pale-red, slightly purple-white, yellow-yellow and thick coating on the tongue and a slippery and rapid pulse. Western diagnosis: coronary heart disease, hypertension, diabetes. Diagnosis of traditional Chinese medicine: chest stuffiness, obstruction of phlegm-heat, malnutrition of heart-mind, and the actions of relieving chest stuffiness, resolving phlegm, nourishing heart, restoring pulse, and tranquilizing mind. The prescription comprises the following components: 10g of codonopsis pilosula, 15g of dwarf lilyturf tuber, 10g of shizandra berry, 10g of coptis chinensis, 15g of purified pinellia tuber, 15g of snakegourd fruit, 15g of allium macrostemon, 15g of magnolia officinalis, 15g of immature bitter orange, 15g of poria cocos, 30g of selfheal, 30g of raw dragon bone (decocted first), 30g of raw oyster (decocted first), 30g of mother-of-pearl (decocted first) and 10g of liquorice. 30 doses, 1 dose daily, are decocted in water and taken for 3 times.
Two diagnoses in 2013, 4 and 12 days: back pain, palpitation, and subjective strength increase, sometimes chest pain and abdominal distention, and nitroglycerin is taken 2 times during the period. Dynamic electrocardiogram: ventricular extra-systole 1577 times/24 h, paroxysmal ST-T changes. Blood pressure is 128/88mmHg. Pale purple tongue with pale yellow and thick coating and slippery pulse. Above, removing fructus Schisandrae chinensis and Concha Margaritifera, adding ramulus Cinnamomi 10g and radix Sophorae Flavescentis 10g.30 doses are decocted and taken as before.
Three diagnoses in 2013, 7, 15 days: the administration of the preparation 90 times above the preparation reduces the times of chest pain, the palpitation basically disappears, and the pain in the precordial region is occasionally caused, and the nitroglycerin is taken for 1 time. Blood pressure 160/90mmHg. A purple tongue with white and thick coating and a slippery pulse. The prescription comprises the following components: ramulus Cinnamomi and fructus Aurantii Immaturus are removed from the upper part, and 10g of Saviae Miltiorrhizae radix, 30g of ramulus Uncariae cum Uncis and 30 doses are added.
Four diagnoses in 2013, 11, 3 and four days: 60 doses above are taken, the pain in the precordial region is basically eliminated, the palpitation is relieved, and the nitroglycerin is not taken. The decoction 120 doses are intermittently taken by the goats in the goats of 10 and 25 days in 2014: first diagonal branch, left anterior descending branch severe stenosis (75% -89%), right coronary artery moderate stenosis (50% -74%). The treatment is carried out by the conservation method, the patients with palpitation are treated by following the diagnosis for 3 years, the nitroglycerin is stopped taking, the biochemical indexes are normal, and no cardiovascular accident occurs.
In terms of: the patient is characterized by chest distress precordial pain and ventricular premature contraction, syndrome differentiation is mainly characterized by phlegm-heat blockage, on the basis of a yang warming and heart benefiting method, dragon bone, oyster and mother-of-pearl are sequentially added, heart is calm and palpitation is calm, chinese magnoliavine fruit and kuh-seng are used for heart nourishing and pulse recovery, magnolia officinalis and immature bitter orange regulate qi and reduce phlegm to regulate heart rhythm, precordial pain of the patient is basically eliminated after treatment, nitroglycerin is stopped taking, and dynamic electrocardiogram is rechecked to display that the ventricular premature contraction is obviously reduced, pulse promotion is not generated, and simultaneously the coronary artery stenosis degree is obviously reduced.
Implementation case 3: patients, men, age 48, were first diagnosed in 2013, 6, 23 days due to "short breath after activity, 1 year back sinking". The following symptoms: shortness of breath after activity, sinking back, aversion to cold, cold limbs, premature ejaculation, suspicion of anxiety and low emotion. Coronary angiography shows: the left anterior descending branch is more than 90% in middle section, the first diagonal branch is 100% occluded, the middle section of the circumflex branch is 50% in middle section, and the right coronary artery is 50% in middle section. Blood pressure 120/70mmHg. The tongue is dark, red, ecchymosis, yellow and white in coating and the pulse is wiry and slippery. Western diagnosis: coronary heart disease. Diagnosis of traditional Chinese medicine: chest stuffiness is caused by heart yang deficiency and stagnation of phlegm stasis, so it is indicated for yang-warming, heart-tonifying, blood-activating and phlegm-resolving. The prescription comprises the following components: 20g of codonopsis pilosula, 15g of dwarf lilyturf tuber, 7g of coptis chinensis, 15g of purified pinellia tuber, 15g of snakegourd fruit, 15g of allium macrostemon, 15g of poria cocos, 15g of red paeony root, 15g of szechuan lovage rhizome, 10g of cassia twig, 15g of immature bitter orange, 10g of common curculigo rhizome, 10g of epimedium herb, 30g of raw dragon bone (decocted first) and 10g of liquorice. 20 doses, 1 dose daily, are decocted in water and taken for 3 times.
Two diagnoses in 2013, 7 and 16 days: shortness of breath, sinking back, reduced anxiety, dizziness due to morning vision, sneeze, aversion to cold, tinnitus, sleep disturbance, and dribbling after urination. Blood pressure 118/82mmHg. The tongue is fat, dark red, slightly purple with white coating, little body fluid, and wiry and slow pulse. Removing ramulus Cinnamomi, rhizoma Curculiginis, herba Epimedii, fructus Aurantii Immaturus, and Os Draconis, and adding fructus Schisandrae 10g, rhizoma Polygonati 2g, periostracum Cicadae 15g, herba Schizonepetae 15g, and caulis Polygoni Multiflori 30g.30 doses are decocted before taking.
Three diagnoses in 2013, 8, 18 days: sneeze, sleep, dribbling after urine, blurred vision, and tinnitus with symptoms of heart condition, lower abdomen, waist and arm on both sides scattered on eczema, and constipation, and 1 time a day. Blood pressure is 128/70mmHg. Pale-red and slightly dark tongue with white coating and wiry and slippery pulse. Removing fructus Schisandrae chinensis, rhizoma Polygonati, periostracum Cicadae, herba Schizonepetae, and caulis Polygoni Multiflori, and adding radix Puerariae 20g, radix Sophorae Flavescentis 10g, kochiae fructus 15g, fructus Vitics Simplicifoliae 15g, and Eucommiae cortex 15g.30 doses are decocted and taken as before.
Four diagnoses in 2013, 9 and 21 days: skin eczema is not treated, but is sometimes treated by nasal obstruction and sneeze, and is sometimes painful in precordial region and comfortable. Blood pressure 130/80mmHg. The decoction is taken after 250 doses of the decoction. Coronary CT for 10 months and 14 days 2014: severe stenosis in the middle of the anterior left descending branch (75-89%), stenosis in the middle of the first diagonal, circumflex branch, and right coronary artery by 50%. The disease is stable after 2 years of diagnosis, and no cardiovascular accident occurs.
In terms of: the patient has the symptoms of anxiety and low emotion on the basis of coronary heart disease. The heart is mainly clear, and the heart yang failing to control can cause emotional changes, and the syndrome differentiation is mainly based on yang deficiency and phlegm stasis, and the yang warming and heart tonifying method is combined with the two immortals Shang Wenyang to benefit the heart, activate blood and resolve phlegm. In the second diagnosis, the patients have shortness of breath, no sinking back, reduced anxiety, but allergic rhinitis, and dribbling urine, and the periostracum Cicadae and herba Schizonepetae are used for dispelling pathogenic wind and desensitizing, and rhizoma Polygonati and fructus Schisandrae chinensis are used for reinforcing kidney and reducing urine. The three diagnosis and treatment are combined with eczema, and the kuh-seng, the fructus kochiae, the wind-dispelling and itching-relieving functions are used for clearing the head and eyes, and the eucommia ulmoides tonifies are used for reinforcing the curative effect. The daoyin treatment is more than 1 year, the first diagonal coronary occlusion is recanalized, and the rest stenosis degree is obviously reduced.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A Chinese herbal compound with the effects of warming yang and tonifying heart is characterized in that: comprises the following components: 5-30 parts of radix codonopsis pilosulae, 5-30 parts of dwarf lilyturf tuber, 5-15 parts of coptis chinensis, 5-30 parts of snakegourd fruit, 5-30 parts of allium macrostemon, 5-9 parts of pinellia tuber, 5-30 parts of cassia twig, 5-30 parts of red paeony root, 5-30 parts of poria cocos, 5-20 parts of szechuan lovage rhizome, 5-15 parts of liquorice, 5-15 parts of ginger and 5-15 parts of Chinese date.
2. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: radix astragali 10-60 parts can be added for regulating chest distress and short breath.
3. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: also comprises 3-10 parts of schisandra chinensis, 10-50 parts of raw dragon bone, 10-50 parts of raw oyster and 10-50 parts of mother-of-pearl for regulating insomnia and palpitation.
4. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: also add 10 parts of cassia twig, and remove all parts of coptis chinensis, and can be used for regulating aversion to cold and cold limbs.
5. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: fructus Aurantii Immaturus 5-20 parts can be added for regulating chest and abdomen fullness and oppression.
6. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: also adding 5 parts of coptis chinensis and removing all parts of dwarf lilyturf tuber for regulating the yellow and thick tongue fur.
7. The traditional Chinese medicine compound with the effects of warming yang and tonifying heart according to claim 1, which is characterized in that: also comprises 5-20 parts of rhizoma Curculiginis, 5-20 parts of cortex Eucommiae and 5-20 parts of radix Morindae officinalis for regulating soreness of waist, aversion to cold, and weakness of lower limbs.
8. A compound decoction method according to any one of claims 1-7, characterized in that:
step one, soaking a compound medicine in clear water before decocting;
step two, pouring the compound medicine into a marmite for first decoction after soaking, wherein the water adding amount exceeds the medicine surface by 10 cm;
step three, decocting the first decoction for 40 minutes after boiling, pouring out the first decoction, and reserving the first decocted compound medicine;
step four, performing second decoction on the compound medicine after the first decoction, wherein the second decoction water quantity is smaller than the first decoction water quantity, boiling, then decocting for 30 minutes, and pouring out the second decoction;
and fifthly, mixing the first decoction amount with the second decoction amount.
9. The method of claim 8, wherein: the compound medicine in the first step is soaked for 30 minutes if the compound medicine is leaf-type or grass-type Chinese medicine, and soaked for one hour if the compound medicine is mineral-type Chinese medicine; the mineral Chinese medicinal materials include Os Draconis, concha Ostreae and Concha Margaritifera.
10. The method of claim 8, wherein: the method of claim 8, wherein: decocting with strong fire when not boiling, decocting with slow fire after boiling, and stirring continuously during the decoction.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211545715.6A CN116077611A (en) | 2022-12-01 | 2022-12-01 | Traditional Chinese medicine compound with yang warming and heart benefiting effects |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211545715.6A CN116077611A (en) | 2022-12-01 | 2022-12-01 | Traditional Chinese medicine compound with yang warming and heart benefiting effects |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116077611A true CN116077611A (en) | 2023-05-09 |
Family
ID=86207149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211545715.6A Pending CN116077611A (en) | 2022-12-01 | 2022-12-01 | Traditional Chinese medicine compound with yang warming and heart benefiting effects |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116077611A (en) |
-
2022
- 2022-12-01 CN CN202211545715.6A patent/CN116077611A/en active Pending
Non-Patent Citations (3)
Title |
---|
刘莹等: "温心方对心肌缺血再灌注损伤大鼠线粒体能量代谢的作用机制", 《中国实验方剂学杂志》, vol. 28, no. 17, pages 52 - 59 * |
曹洪欣;: "温阳益心法治疗冠心病冠状动脉狭窄验案3则", 中医杂志, no. 10, pages 880 - 881 * |
李春杰;谷素洁;曹洪欣;段颖;: "温阳益心法治疗急性冠脉综合征的临床研究", 中医药学报, no. 04, pages 55 - 57 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108969642B (en) | A Chinese medicinal compound external preparation for treating chronic prostatitis, and its preparation method | |
CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
CN116370556B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, tonifying qi and soothing nerves and preparation method thereof | |
CN116617328A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris phlegm-blood stasis syndrome | |
CN115177669B (en) | Traditional Chinese medicine composition with efficacy of treating myocardial bridge and application thereof | |
CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
US20030143289A1 (en) | Herbal composition PHY828 and its use | |
CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
CN115252691A (en) | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina | |
CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
CN116077611A (en) | Traditional Chinese medicine compound with yang warming and heart benefiting effects | |
CN113274471A (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases, preparation method and application | |
CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
CN113144080B (en) | Traditional Chinese medicine for treating coronary atherosclerotic plaques | |
CN114848724B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
CN116327825B (en) | A Chinese medicinal composition for treating cardiovascular diseases, and its preparation method | |
CN113786471B (en) | Traditional Chinese medicine composition for treating cardiac pain | |
CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
CN116870100A (en) | Traditional Chinese medicine compound composition for treating obesity-related hypertension and preparation method thereof | |
CN105983053B (en) | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method | |
CN118001362A (en) | Traditional Chinese medicine composition, preparation and application for treating qi deficiency and blood stasis type coronary heart disease angina or PCI postoperative angina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230509 |